CRDF — Cardiff Oncology Cashflow Statement
0.000.00%
Last trade - 00:00- $187.60m
- $94.76m
- $0.68m
Annual cashflow statement for Cardiff Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -19.3 | -28.3 | -38.7 | -41.4 | -45.4 |
| Depreciation | |||||
| Non-Cash Items | 3.18 | 6.59 | 5.03 | 3.59 | 4.16 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.655 | -1.79 | -0.38 | 6.57 | 3.17 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -16.3 | -23 | -33.8 | -30.9 | -37.7 |
| Capital Expenditures | -0.212 | -0.205 | -1.01 | -0.582 | -0.08 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -131 | 39.2 | 36.8 | 13.8 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.212 | -131 | 38.1 | 36.2 | 13.7 |
| Financing Cash Flow Items | -0.007 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 137 | 35.5 | 0.075 | 0 | 53.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 121 | -119 | 4.4 | 5.31 | 29.8 |